Side-by-side · Research reference
MGFvsSermorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED14/55 cited
BPhase 3HUMAN-REVIEWED14/43 cited
MGF
IGF-1Ec Splice Variant · Muscle-Specific
SQ · Research context only
Sermorelin
GHRH 1-29 fragment · Short-acting
SQ · Pre-sleep · 1×/day
01Mechanism of Action
Parameter
MGF
Sermorelin
Primary target
Satellite cells (Pax7+) in skeletal muscleMoore 2018
Pituitary GHRH receptorWalker 1994
Pathway
Mechanical stress → IGF-1Ec mRNA upregulation → Local E-domain peptide release → Satellite cell activation
GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994
Downstream effect
Satellite cell proliferation, myoblast differentiation, muscle fiber repair
Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013
Feedback intact?
—
Yes — short pulse preserves feedback
Origin
Alternative splicing of IGF-1 gene (exons 4-6) produces IGF-1Ec precursor; E-domain cleaved post-translationallyArmakolas 2016Vassilakos 2017
Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994
Antibody development
—
—
02Dosage Protocols
Parameter
MGF
Sermorelin
Synthetic peptide
24-amino-acid E-domain sequence
Corresponds to human IGF-1Ec exons 4-6 region.
—
Rodent cardiac model
200 μg/kg via peptide-eluting microstructures
Post-MI injection; improved ejection fraction by 8 weeks.
—
Acute delivery (mouse MI)
Single bolus within 12 hrs post-infarctionShioura 2014
Delayed decompensation; no human protocol established.
—
Human evidence
None — no published clinical trials
All dosing extrapolated from animal models.
—
Detection in doping
Full-length MGF detected via LC-MS in illicit productsThevis 2014
WADA-prohibited since 2005; no therapeutic indication.
—
Evidence basis
Animal models + in vitro only
Phase 3 (Geref pediatric); clinical practiceWalker 1994Molteno 2013
Frequency
—
Once daily, pre-sleep
Lower / starter dose
—
100 mcg per dose
Duration
—
8–12 weeks per cycle
Reconstitution
—
Bacteriostatic water
Timing
—
Pre-sleep, fasted preferred
04Side Effects & Safety
Parameter
MGF
Sermorelin
Human safety data
None — no clinical trials published
—
Theoretical IGF-1 axis risk
Chronic IGF-1Ec overexpression linked to cancer progression (prostate, colorectal, breast)
—
Tumor promotion
IGF-1Ec overexpressed in osteosarcoma, colorectal polyps with dysplasia, endometrial cancer
—
Antibody development
Unknown — no longitudinal human exposure data
—
Local injection reaction
Presumed similar to other peptides (erythema, induration) — no direct evidence
—
Dysregulated expression with age
Older adults (70+ yrs) show blunted IGF-1Ec response post-exercise vs youngMoore 2018
—
Injection site reaction
—
Mild erythema, transient pain
Flushing / headache
—
Common transient effect
IGF-1 elevation
—
Modest at standard doses
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis)
Pregnancy / OB
—
Avoid
Glucose handling
—
Generally neutral
Absolute Contraindications
MGF
- ·Active malignancy or history of IGF-1-sensitive cancers (prostate, colorectal, breast, osteosarcoma)
- ·No established therapeutic use — investigational only
Sermorelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
MGF
- ·Family history of IGF-1-axis malignancies
- ·Use outside research setting
Sermorelin
- ·Untreated diabetes
05Administration Protocol
Parameter
MGF
Sermorelin
1. No validated protocol
MGF (E-domain peptide) has no approved clinical protocol. All published data derive from animal models or in vitro experiments.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Synthetic peptide form
Commercially available MGF corresponds to the 24-amino-acid human E-domain (hEc). Rodent E-domain (Eb) is structurally distinct and not interchangeable.
SQ — abdomen or thigh. Rotate sites.
3. Animal delivery models
Rodent studies used peptide-eluting polymeric microstructures (cardiac) or direct intramuscular injection. Routes and doses non-translatable to humans.Peña 2015Shioura 2014
Pre-sleep, fasted.
4. WADA prohibition
MGF peptides prohibited in sport since 2005. Detection via LC-MS established for full-length MGF products.Thevis 2014
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Research context only
Any human use falls outside approved medical practice and regulatory frameworks. No safety or efficacy data exist.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
MGF
+ BPC-157
Multi-pathwayMGF activates satellite cells for muscle fiber repair; BPC-157 promotes angiogenesis, collagen synthesis, and tendon healing via distinct pathways (VEGF, FAK, integrin signaling). Theoretical synergy in post-injury contexts combines myogenic (MGF) and stromal (BPC-157) repair mechanisms. Both lack human validation.
- MGF
- No established dose
- BPC-157
- 250–500 mcg SQ near injury site
- Context
- Animal models only
- Primary benefit
- Theoretical multi-tissue repair (muscle + tendon/ligament)
+ TB-500
ModerateTB-500 (thymosin beta-4 fragment) enhances actin polymerization, cell migration, and angiogenesis—complementary to MGF satellite cell activation. Both upregulated post-injury; combined use presumed additive for muscle regeneration in preclinical models.
- MGF
- No established dose
- TB-500
- 2–5 mg SQ weekly
- Context
- Animal models only
- Primary benefit
- Satellite cell activation + enhanced migration/angiogenesis
Sermorelin
+ Ipamorelin
StrongSermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.
- Sermorelin
- 200–300 mcg SQ · pre-sleep
- Ipamorelin
- 200–300 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation, recovery, body composition